On June 12, 2019, 15 US Senators introduced S.1801, a bill to make medicines more affordable. Among the provisions in the bill are a study of the feasibility of progressively delinking R&D costs from product prices. S. 1801: Affordable Medications Act Ms. Smith (for herself, Ms. Klobuchar, Mr. Blumenthal, Mr. Udall, Mr. Brown, Ms. Warren, Read more about S. 1801: Affordable Medications Act (116th Congress), calls for study of delinkage[…]
On December 2, 2016, Knowledge Ecology International hosted a technical meeting on delinkage at the United States Senate. The meeting included panels on various aspects of delinkage, including end product prizes, open source dividends, and antibiotics. Slide presentations from the meeting are available on the KEI website. A recording of the event is on YouTube.
By Dean Baker, Co-Director, the Center for Economic and Policy Research (CEPR) September 11, 2016 Every economist knows that trade tariffs are bad because they raise the price of the protected product above the free market price. The story is the same with patent monopolies on prescription drugs. However, there are two big differences. Tariffs Read more about The Economics of Delinkage[…]